Analysts Set Agenus Inc. (NASDAQ:AGEN) Price Target at $10.00

Agenus Inc. (NASDAQ:AGEN) has received an average recommendation of “Hold” from the six analysts that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $10.00.

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a research note on Wednesday, January 22nd.

Agenus Stock Down 7.7 %

AGEN opened at $3.23 on Tuesday. The stock’s 50 day moving average price is $3.26 and its two-hundred day moving average price is $4.22. The firm has a market capitalization of $75.78 million, a P/E ratio of -0.29 and a beta of 1.31. Agenus has a 12-month low of $2.50 and a 12-month high of $19.69.

Hedge Funds Weigh In On Agenus

Several large investors have recently added to or reduced their stakes in AGEN. EP Wealth Advisors LLC bought a new stake in shares of Agenus during the third quarter valued at approximately $55,000. Point72 DIFC Ltd boosted its stake in Agenus by 380.0% during the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after buying an additional 11,542 shares in the last quarter. Apollon Wealth Management LLC bought a new stake in Agenus in the 4th quarter valued at $55,000. HighTower Advisors LLC raised its stake in shares of Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 7,530 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in shares of Agenus by 52.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 9,422 shares in the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.